Latest filing published 01 Mar 2022 for Regulus Therapeutics Inc., €16k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Denis Drygin: trading record in brief
Denis Drygin (senior executive) discloses dealings in Regulus Therapeutics Inc. to SEC (Form 4). Between 4 February 2022 and 1 March 2022, the trades on record add up to 2 filings.
The open-market record is one-sided, with 2 purchases worth €20k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The newest entry dates from 1 March 2022: an open-market purchase of €16k, in Regulus Therapeutics Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Denis Drygin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 76,686 shares@ US$0.2377.0% of flowCommon StockSEC:0001209191-22-014248:0Canonical exit: 30 May 2022 (T+90)
- 23,314 shares@ US$0.2323.0% of flowCommon StockSEC:0001209191-22-007506:0Canonical exit: 5 May 2022 (T+90)
2 of 2 declarations
